<DOC>
	<DOCNO>NCT00002833</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . Colony stimulate factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness peripheral stem cell transplantation plus filgrastim treating patient acute chronic myelogenous leukemia .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Plus Filgrastim Treating Patients With Acute Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect feasibility use filgrastim promote hematopoietic recovery leukemia control intensive nonmyeloablative salvage chemotherapy . II . Determine engraftment kinetics degree chimerism achievable . OUTLINE : The trial 2 patient group . Patients remission assign group 1 , patient remission assign group 2 . Then , group divide 2 treatment arm . Patients fail fludarabine therapy receive cytarabine ( Ara-C ) IV 2 hour day -7 , -6 , -5 , -4 -3 . Beginning 4 hour first dose Ara-C , patient receive cladribine ( 2-chlorodeoxyadenosine ; 2-CdA ) continuous infusion 5 day . Patients without prior fludarabine therapy receive fludarabine IV 30 minute daily day -6 , -5 , -4 -3 . Ara-C IV begin 4 hour begin fludarabine infusion continue 4 hour . Idarubicin IV give day -6 , -5 -4 . Donors receive filgrastim SC every 12 hour 2 day prior stem cell collection . Cells infuse day 0 . For GVHD prophylaxis , patient receive cyclosporine via continuous IV infusion . Oral cyclosporine administer patient tolerate oral feed continued 6 month postinfusion . Then , dose cyclosporine taper 10 % weekly discontinue . Methylprednisolone begin 5 day infusion gradually taper . PROJECTED ACCRUAL : A maximum 15 patient per arm likely enter 24 36 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute leukemia poor risk cytogenetic feature ( 5,7 , +8 ) first complete remission Poor risk myelodysplasia Refractory anemia excess blast ( RAEB ) RAEB transformation ( RAEBT ) Chronic myelomonocytic leukemia ( CMML ) Chronic myelogenous leukemia ( CML ) late chronic phase Acute leukemia great first complete remission transform CML CMML PATIENT CHARACTERISTICS : Age : 55 65 65 70 ( discretion study chairperson basis performance status ) 55 ( decline conventional high dose chemotherapy due concurrent medical condition ( i.e . ejection fraction less 50 , FEV1 , FVC , DLCO le 50 % , abnormal LFTs ) Performance status : Zubrod le 2 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 3 mg/dL Renal : Serum creatinine le 2 mg/dL Cardiovascular : Ejection fraction great 40 % per MUGA scan Pulmonary : Not specify Other : No active uncontrolled infection HLA compatible donor capable donate stem cell via apheresis PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>graft versus host disease</keyword>
</DOC>